M. Taton
-
- Thyroid Disorders and Treatments 6
- Growth Hormone and Insulin-like Growth Factors 3
-
- Cancer Treatment and Pharmacology 3
- HER2/EGFR in Cancer Research 2
- Cancer-related Molecular Pathways 2
-
- Microtubule and mitosis dynamics 2
-
- Cancer Genomics and Diagnostics 2
-
- Lung Cancer Treatments and Mutations 5
M. Taton
16 papers receiving 600 citations
Peers
Comparison fields: 5 of 63
- Endocrinology, Diabetes and Metabolism 270
- Oncology 180
- Cell Biology 93
- Molecular Biology 332
- Cancer Research 65
Countries citing papers authored by M. Taton
This map shows the geographic impact of M. Taton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Taton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Taton more than expected).
Fields of papers citing papers by M. Taton
This network shows the impact of papers produced by M. Taton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Taton. The network helps show where M. Taton may publish in the future.
Co-authorship network
The 25 scholars most cited alongside M. Taton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 132 | |
| 2 | 2010 | 6 | |
| 3 | Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu | 2009 | 20 |
| 4 | 2009 | 9 | |
| 5 | 2009 | 11 | |
| 6 | 2008 | 8 | |
| 7 | A phase I dose finding study of a 3-day administration of BIBW 2992, an irreversible dual EGFR/HER2 inhibitor, in combination with 3-weekly docetaxel in patients with advanced solid tumors | 2007 | 1 |
| 8 | 1999 | 47 | |
| 9 | 1996 | 7 | |
| 10 | 1995 | 9 | |
| 11 | 1995 | 2 | |
| 12 | 1994 | 54 | |
| 13 | 1994 | 70 | |
| 14 | 1993 | 56 | |
| 15 | The TSH cyclic AMP cascade in the control of thyroid cell proliferation: the story of a concept. | 1991 | 16 |
| 16 | 1990 | 28 | |
| 17 | 1988 | 159 |
About M. Taton
M. Taton is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology, Hepatology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 17 papers that have together received 635 indexed citations. Recurring topics across this work include Thyroid Disorders and Treatments (6 papers), Lung Cancer Treatments and Mutations (5 papers), Growth Hormone and Insulin-like Growth Factors (3 papers), Cancer Treatment and Pharmacology (3 papers), HER2/EGFR in Cancer Research (2 papers), Cancer-related Molecular Pathways (2 papers), Cancer Genomics and Diagnostics (2 papers) and Microtubule and mitosis dynamics (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (270 citations), Oncology (180 citations), Cell Biology (93 citations), Molecular Biology (332 citations) and Cancer Research (65 citations). M. Taton has collaborated with scholars based in Belgium, Germany and France. Frequent co-authors include Jacques E. Dumont, Pierre P. Roger, Jacqueline Van Sande, Françoise Lamy, Thierry Velu, R Paschke, Frank Schuppert, Ahmad Awada, Patrick Schöffski and Holger Fritsch. Their work appears in journals such as Molecular and Cellular Endocrinology, Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism, Endocrinology and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.